Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Efficacy of Spearmint Tea in Relieving Osteoarthritis of the Knee

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Veza se sprema u međuspremnik
StatusZavršeno
Sponzori
University of Guelph
Saradnici
Ontario Ministry of Agriculture, Food and Rural Affairs

Ključne riječi

Sažetak

The purpose of this study is to investigate the benefits of daily consumption of a high rosmarinic acid spearmint tea, developed by the University of Guelph, on measures of pain, physical function and disease activity in osteoarthritis of the knee.
The investigators hypothesize that a spearmint tea high in rosmarinic acid is efficacious in mitigating the symptoms of osteoarthritis of the knee through its actions in reducing cartilage degradation, oxidative stress and inflammation.

Opis

Healthy adults with a clinical diagnosis of osteoarthritis of the knee will be recruited and will undergo a brief phone screening interview, followed by a detailed in-person screening process, to determine study eligibility.

Eligible participants will be matched according to sex, baseline pain according to the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score, and duration of osteoarthritis. Participants will then be randomly assigned to receive either the investigative high rosmarinic acid spearmint tea or a comparable placebo mint tea.

During the 4-month treatment period, participants will consume two cups (300 mL in the morning and 300 mL in the evening) of either the high rosmarinic acid spearmint tea (approximately 300 mg rosmarinic acid per day) or the commercial spearmint tea (approximately 20 mg of rosmarinic acid per day) daily.

Data collection will occur at baseline (week 0), mid-treatment (week 8), post-treatment (week 16), and follow-up (week 20). Outcome measures include WOMAC and SF-36 scores, physical function (6-minute walk, stair climb task), inflammatory markers (serum C-reactive protein), and self-reported changes in pain medication use. In a sub-set of consenting participants deemed eligible by the study physician, a synovial fluid sample will be drawn from the knee for the analyses of cartilage degradation biomarkers (GAG, COMP, PGE2, NO) at baseline (week 0) and post-treatment (week 16).

Datumi

Posljednja provjera: 12/31/2012
Prvo podneseno: 06/20/2011
Predviđena prijava predata: 06/22/2011
Prvo objavljeno: 06/26/2011
Zadnje ažuriranje poslato: 01/20/2013
Posljednje ažuriranje objavljeno: 01/22/2013
Stvarni datum početka studija: 06/30/2011
Procijenjeni datum primarnog završetka: 10/31/2012
Predviđeni datum završetka studije: 11/30/2012

Stanje ili bolest

Osteoarthritis of the Knee

Intervencija / liječenje

Other: Placebo Control

Other: Experimental

Faza

Faza 4

Grupe ruku

ArmIntervencija / liječenje
Placebo Comparator: Placebo Control
Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
Other: Placebo Control
Commercially available, non-selectively bred spearmint tea.
Experimental: Experimental
Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
Other: Experimental
The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.

Kriteriji prihvatljivosti

Uzrast podoban za studiranje 18 Years To 18 Years
Polovi podobni za studiranjeAll
Prihvaća zdrave volontereDa
Kriterijumi

Inclusion Criteria:

- Is at least 18 years or older

- Have been diagnosed by a health care professional with osteoarthritis of the knee

- Demonstrates a WOMAC pain score greater then 125 at time of study screening

Exclusion Criteria:

- Has any other systemic or rheumatic arthritis

- Has completed or is planning to undergo knee replacement surgery

- Has had a chemical, radiologic, or surgical synovectomy in any large joint within the previous 3 months

- Has any concomitant inflammatory processes such as infectious or rheumatic disease

- Has any gastrointestinal ulcers

- Has any clinically significant, uncontrolled cardiovascular, hepatic, renal, or any other medical condition that may interfere with the study

- Has any serious medication conditions such as recent (within the previous 6 months) heart attack, stroke, cancer and/or diabetes

- Has a recent history (within the previous 6 months) of a clinically significant psychiatric disorder other than mild depression

- Has a known allergy or hypersensitivity to mint or any other food allergies

- Smokes, drinks alcohol (>14 drinks per week) or participates in recreational drug use

- Has participated in a clinical trial involving an investigational or marketed drug within the previous 6 months

- Women who are pregnant or plan to become pregnant during the study period, women who have recently (within the previous 6 months) given birth, women who are currently lactating or have only recently (within the previous 6 months) stopped lactating.

Ishod

Primarne mjere ishoda

1. Self-reported ratings of pain and physical function [Four months]

Data collection of self-reported ratings of pain and physical function (WOMAC), self-reported ratings of overall physical and mental health (SF-36), and self-reported changes in the use of concomitant pain and inflammation medications (study diary) will occur at baseline (week 0), mid-treatment (week 8), post-treatment (week 16), and follow-up (week 20).

2. Use of concomitant pain/inflammatory medications for the management of osteoarthritis symptoms [Four months]

Sekundarne mjere ishoda

1. Performance-based measures of physical function [Four months]

Data for performance-based assessment of physical function (6-minute walk, stair climb task) will be collected at baseline (week 0), mid-treatment (week 8), post-treatment (week 16), and follow-up (week 20).

2. Change in synovial fluid biomarkers of cartilage degradation [Four months]

In a sub-set of participants, a synovial fluid sample will be drawn (i.e. arthocentesis) for the analyses of cartilage degradation biomarkers (GAG, COMP, PGE2, NO) at baseline (week 0) and post-treatment (week 16).

Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta naukom

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti naukom
  • Prepoznavanje biljaka po slici
  • Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
  • Pročitajte naučne publikacije povezane sa vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima

Google Play badgeApp Store badge